EN DE
Watch Medincell SA for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Medincell SA (MEDCL) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Medincell SA stock €13.37, price €29.76, that is 55.1% below the price, quality 26 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare FR · ISIN FR0004065605

MS Medincell SA logo Thin data Nov 10, 2026

Medincell SA

MEDCL · PA
Very expensive, weak quality

Our calculation puts a fair price 55% below what the stock costs today.

Expensive Growth (revenue 5y +24.3 %/yr in EUR)
Revenue last quarter 45% below a year ago.
Fair value €13.37 · Strongly overvalued
Quality 26/100
Loss-making · -128.9% net margin (TTM)
High debt
Negative free cash flow
Trails peers (1/9)
Narrow moat 14/100 · thin data
Thin data
Estimate
Watch Medincell SA for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

€38.46 €4.77 Fair Value €13.37 Sep 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range €4.77 – €38.46 · fair‑value band €10.03 – €16.72 · the €29.76 price screens above the €13.37 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Medincell in your weekly email

Every Wednesday you see whether Medincell is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

MedinCell S.A., a clinical-stage and commercial biopharmaceutical licensing company, develops long acting injectables in various therapeutic areas in France. The company develops solutions based on BEPO, a long-acting injectable technology.

Show moreShow less

It offers UZEDY (mdc-IRM) for the treatment of schizophrenia in adults and bipolar I disorder.

It is also developing mdc-TJK, a subcutaneous injection that is in the NDA preparation stage for the treatment of schizophrenia in adults; and mdc-CWM, a sustained-release formulation of celecoxib in Phase III trials for use in the treatment of reduction of postoperative pain and inflammation in total knee arthroplasty surgery.

In addition, its product candidates in preclinical trials include mdc-WWM for contraception; and mdc-STM for malaria.

It has strategic collaborations with AbbVie to develop, manufacture, and commercialize six long-acting injectable therapeutic products; and IM4TB to develop a long-acting injectable version of Macozinone for the treatment of tuberculosis.

MedinCell S.A. was incorporated in 2003 and is based in Jacou, France.

Stock analysis

Medincell SA (MEDCL) currently trades at €29.76, while our estimate is €13.37, 55% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: €10.03 (bear) to €16.72 (bull), the price of €29.76 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 26/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Medincell SA reported revenue of €24.3M in FY2026 versus €4.1M in FY2022, a compound +56.1%/yr. Reported net income was −€31.3M in FY2026.

Key figures

Market cap €1.1B Small · P/S ratio 39.3 · EPS (TTM) €−0.9300 · Net margin −129% · Return on assets (EBIT) −45.6% (5-year average) · Operating margin −140% · Revenue (TTM) €24.3M · Revenue growth (YoY) −44.6%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 14 out of 100 (low confidence).

What moves the price

The share trades about 3% below its 52-week high and 47% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −55%, MEDCL screens richer than that median.

Fair Value

Bear €10.03 Fair Value €13.37 Bull €16.72
Price €29.76 · Downside -55.1%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 26/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 10
How much profit the company makes from its sales and capital
Quality Growth 14
Are margins and returns getting better?
Cashflow 30
Do the profits arrive as real cash?
Financial strength 50
Debt, balance sheet and risk of trouble
Investment 50
Does it invest with discipline instead of growing at any price?
Low Volatility 40
How calm the share price moves, does not count
Price momentum 53
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 62
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 38/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−4.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+34.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+24.3%
Start year 2021 (pandemic). Over 10 years: +11.4% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.4%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−190.7% (2021) → −105.0% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed

MEDCL screens overvalued: fair value 55% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Medincell SA with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 0/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 26 · Bottom 25%
Fair Value upside −55.1% · Bottom 25%
Profitability
Return on assets −29.0% · Below median
Net margin (12 months) −128.9% · Bottom 25%
Operating margin (12 months) −139.5% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −44.6% · Bottom 25%
Balance sheet
Debt / equity 17.10× · Highest 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/S (12 months) 44.02× · Priciest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs MEDCL
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs MEDCL
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs MEDCL
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs MEDCL
argenx SE ARGX $971.55 $908.40 −7% vs MEDCL
CSL Limited CSL A$201.68 A$181.40 −10% vs MEDCL
Moderna, Inc MRNA $250.83 $158.70 −37% vs MEDCL
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs MEDCL
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs MEDCL
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs MEDCL

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Medincell SA: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Medincell SA Fair Value". https://www.fairvalue-calculator.com/stock/MEDCL

Frequently asked questions

Is Medincell SA (MEDCL) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is €13.37 versus a price of €29.76, about 55% lower (overvalued).
What is the fair value of MEDCL?
Our estimate for Medincell SA is €13.37 (as of Nov 10, 2026), built from audited fundamentals. The current price: €29.76.
What is the quality score of MEDCL?
Medincell SA has a Quality Score of 26/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Medincell SA (MEDCL)?
Our calculated price target is the estimate of €13.37 (as of Nov 10, 2026). Cautious scenario €10.03, optimistic scenario €16.72. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Medincell SA stock forecast for 2026?
Our estimate puts fair value at €13.37, about 55% lower versus a price of €29.76 (overvalued). Cautious scenario €10.03, optimistic scenario €16.72. The calculation is refreshed regularly with new filings.
What is the revenue of Medincell SA (MEDCL)?
Medincell SA reported trailing-twelve-month revenue of about €24.3M (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Medincell SA (MEDCL)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Medincell SA it is €13.37 per share (as of Nov 10, 2026), against a price of €29.76.
Is Medincell SA stock overvalued or undervalued in 2026?
As of Nov 10, 2026, MEDCL trades above its calculated fair value: price €29.76, fair value €13.37, a gap of about −55% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MEDCL?
No. The price is what the market pays today (€29.76); the fair value is what the company's own numbers justify (€13.37). For Medincell SA the two are €16.39 per share apart. That gap is exactly why we show both numbers side by side.
How much is Medincell SA worth?
The market values Medincell SA at about €1.1B (market capitalisation, as of Nov 10, 2026). Per share that is €29.76; our models calculate a fair value of €13.37 per share.
What do the bullish and bearish scenarios say about MEDCL?
Our models span a range for Medincell SA: cautious scenario €10.03, base €13.37, optimistic €16.72 per share (as of Nov 10, 2026, price €29.76). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Medincell SA (MEDCL)?
Balance-sheet figures for Medincell SA (as of Nov 10, 2026): debt of 17.10 per unit of equity. They feed the Quality Score of 26/100, which measures business quality independently of the share price.
How far is MEDCL from its 52-week high?
Medincell SA trades at €29.76, about 3% below its 52-week high of €30.72 and 47% above the low of €20.24 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of €13.37 is for.
Which stocks are comparable to Medincell SA?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Medincell SA stock attractive at the current price?
The data as of Nov 10, 2026: price €29.76, calculated fair value €13.37 (−55%), Quality Score 26/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Medincell SA itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Medincell SA (MEDCL)?
The closing price on Nov 10, 2026 was €29.76. Our estimate is €13.37, about 55% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Medincell SA right now?
The price sits above even our optimistic bull case (€16.72). The favourable scenario is already priced in. Weak quality (26/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Medincell SA

How large is the market capitalisation of Medincell SA (MEDCL)?
The market capitalisation of Medincell SA is €1.1B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Medincell SA (MEDCL)?
The price-to-sales ratio of Medincell SA is 39.3 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Medincell SA (MEDCL)?
Earnings per share at Medincell SA are €−0.9300. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Medincell SA (MEDCL)?
The net margin of Medincell SA is −129% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the EBIT return on assets of Medincell SA (MEDCL)?
On an EBIT basis the return on assets of Medincell SA is −45.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Medincell SA (MEDCL)?
The operating margin of Medincell SA is −140% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Medincell SA (MEDCL)?
Revenue at Medincell SA is growing −44.6% versus a year earlier (3y avg +34.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Medincell SA (MEDCL) generate?
The free cash flow of Medincell SA is −€24.6M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Medincell SA (MEDCL) hold?
Medincell SA holds more cash than debt, €5.4M net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Medincell SA in the live analysis

One click puts Medincell SA on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.